Ganglion cell death causes loss of vision in glaucoma by increasing the intraocular pressure due to loss of neuroprotective strategy. Diabetes mellitus is a condition in which a person has a high blood sugar level as a result of the body either not producing enough insulin or insulin resistance to body cells ( NIDDM ). Drug Designing, one of the hottest topics have found its new pathway to create a history in the field of medical science. The lead compound analysis starts with CADD, assisting to identify and optimise the right compound. In the following study, molecular modelling method has been used for modelling a new molecule for Glaucoma and NIDDM using Metipranolol, a drug that’s already designed. Its R group is modified by replacing different functional groups like OH, Br, CH2CH3, CH3, Cl, F, H and NH2 and docked with specific protein with help of softwares. The molecules designed as such are optimised using different algorithms. Their affinity and binding free energy checked with protein. The molecule with minimum binding energy will have the maximum binding affinity. From the results obtained it’s clear that ligand 3 and 6 ( -6.85 & -6.79 ) have the maximum binding affinity. So these molecules are determined as the best lead molecules targeting computationally.
